Melanoma Vaccine Greenville NC

A vaccine for advanced melanoma has shown promise in a new study. Melanoma is the most serious type of skin cancer in Greenville. The five year-survival rates for local and metastatic melanoma are 65 percent and 16 percent, respectively. In 2009, an estimated 69,000 people in the United States will be diagnosed with melanoma and about 8,600 will die of the disease, according to the American Cancer Society.

Greenville Veterinary Hospital
(252) 752-1890
1523 East 14th Street
Greenville, NC

Data Provided by:
Kelly W Philpot
(252) 744-1122
1204 E Fire Tower Rd
Greenville, NC
Specialty
Family Practice

Data Provided by:
Thomas J Ellis
(252) 744-1122
1204 E Fire Tower Rd
Greenville, NC
Specialty
Family Practice

Data Provided by:
Jodi Lynn Adler
(252) 355-0000
505 Greenville Blvd Se
Greenville, NC
Specialty
Family Practice

Data Provided by:
Shirley T Williamson
(252) 328-6841
1001 East 5th Street
Greenville, NC
Specialty
General Practice, Family Practice

Data Provided by:
Angela B Mebane
(252) 744-1122
1204 E Fire Tower Rd
Greenville, NC
Specialty
Family Practice

Data Provided by:
Judith Salle Yongue, MD
(252) 355-2768
107 Commerce St Ste D
Greenville, NC
Specialties
Psychiatry, General Practice
Gender
Female
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1962
Hospital
Hospital: Pitt County Memorial Hospital, Greenville, Nc
Group Practice: Judith Yongue Psychiatric Med

Data Provided by:
Charles E Jahrsdorfer
(252) 756-3713
3282 Charles Blvd
Greenville, NC
Specialty
Family Practice

Data Provided by:
Joseph C Jordan
(252) 355-4357
1913 E Fire Tower Rd
Greenville, NC
Specialty
Family Practice, Internal Medicine

Data Provided by:
Teresa A Smith
(252) 353-1464
1688 E Arlington Blvd
Greenville, NC
Specialty
Internal Medicine

Data Provided by:
Data Provided by:

Melanoma Vaccine

Provided By:

SATURDAY, May 30 (HealthDay News) --A vaccine for advanced melanoma has shown promise in a new study.

Melanoma is the most serious type of skin cancer. The five year-survival rates for local and metastatic melanoma are 65 percent and 16 percent, respectively. In 2009, an estimated 69,000 people in the United States will be diagnosed with melanoma and about 8,600 will die of the disease, according to the American Cancer Society.

The study, a phase 3 clinical trial involving 185 people, found that using the peptide vaccine in combination with the immunotherapy drug Interleukin-2 improved response rates and progression-free survival, according to University of Texas M.D. Anderson Cancer Center researchers, who said it was the first phase 3 trial to show a clinical benefit in a vaccine for melanoma.

Response rate and progression-free survival were 22.1 percent and 2.9 months, respectively, in people given the vaccine, compared with 9.7 percent and 1.6 months for those who were not vaccinated. Median overall survival was 17.6 months for the vaccine group and 12.8 months for the others.

The study, which was to be presented Saturday at the annual meeting of the American Society of Clinical Oncology in Orlando, Fla., was funded in part by Novartis, which makes Interleukin-2.

"Obviously this is a disease, in its advanced setting, in need of better therapies for our patients," study co-author Dr. Patrick Hwu, a professor and chairman of M.D. Anderson's Department of Melanoma Medical Oncology, said in a news release from the center.

"While more follow-up is needed, this study serves as a proof-of-principle for vaccines' role in melanoma and in cancer therapy overall," Hwu said. "If we can use the body's own defense system to attack tumor cells, we provide a mechanism for ridding the body of cancer without destroying healthy tissue."

The vaccine, called gp100:209-217 (200M), works by stimulating T-cells, which control immune response.

"This vaccine activates the body's cytotoxic T-cells to recognize antigens on the surface of the tumor," Hwu said. "The T-cells then secrete enzymes that poke holes in the tumor cell's membrane, causing it to disintegrate."

More information

The Skin Cancer Foundation has more about melanoma.

SOURCE: University of Texas M.D. Anderson Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com